[
  {
    "ts": "2026-01-31T05:12:13+00:00",
    "headline": "Assessing Guardant Health (GH) Valuation After FDA Guardant360 CDx Approval And New Merck Collaboration",
    "summary": "Guardant Health (GH) is back in focus after the FDA approved its Guardant360 CDx liquid biopsy as a companion diagnostic for BRAF V600E-mutant metastatic colorectal cancer and the company announced a multi-year collaboration with Merck. See our latest analysis for Guardant Health. These regulatory and partnership updates come after a strong run, with the latest share price at $114.04, a 30 day share price return of 11.65% and a 1 year total shareholder return of 142.74%. However, the 5 year...",
    "url": "https://finance.yahoo.com/news/assessing-guardant-health-gh-valuation-051213684.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "3c827035-3fdb-30b4-a7a2-90ef566353e0",
      "content": {
        "id": "3c827035-3fdb-30b4-a7a2-90ef566353e0",
        "contentType": "STORY",
        "title": "Assessing Guardant Health (GH) Valuation After FDA Guardant360 CDx Approval And New Merck Collaboration",
        "description": "",
        "summary": "Guardant Health (GH) is back in focus after the FDA approved its Guardant360 CDx liquid biopsy as a companion diagnostic for BRAF V600E-mutant metastatic colorectal cancer and the company announced a multi-year collaboration with Merck. See our latest analysis for Guardant Health. These regulatory and partnership updates come after a strong run, with the latest share price at $114.04, a 30 day share price return of 11.65% and a 1 year total shareholder return of 142.74%. However, the 5 year...",
        "pubDate": "2026-01-31T05:12:13Z",
        "displayTime": "2026-01-31T05:12:13Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/0fc6188304291c4515eba03ba128db49",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/PPltrydZQyFx0FwyDTKiqQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/0fc6188304291c4515eba03ba128db49.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/nAhCdmsJrPs7INBkXmkXpA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/0fc6188304291c4515eba03ba128db49.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/assessing-guardant-health-gh-valuation-051213684.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/assessing-guardant-health-gh-valuation-051213684.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GH"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]